The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure
NCT ID: NCT00978653
Last Updated: 2009-09-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2008-04-30
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Uric Acid and the Endothelium in CKD
NCT01228903
Effect of Allopurinol Treatment on Insulin Resistance
NCT02008968
Effect of Allopurinol on Markers of Mineral and Bone Metabolism
NCT05601271
Optimal Administration of Allopurinol in Dialysis Patients
NCT02477488
A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
NCT00793585
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Allopurinol
Hyperuricemic (uric acid (UA)\>7 mg/dL), nondiabetic CKD patients without any comorbidity, age\<60 years with creatinine clearance (CrCl) between 20 and 60ml/min were evaluated.
allopurinol
150 mg once a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
allopurinol
150 mg once a day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients between ages of 18 and 60 years
* Non-diabetic patients
* Creatinine clearance values between 20 and 60 mL/min/1.73 m2
Exclusion Criteria
* Patients with diabetes mellitus, ischemic heart disease, acute coronary syndrome, congestive heart failure (CHF) (New York Heart Association class II or greater), valvular heart disease and a history of cerebral infarction or transient ischemic attack.
* Patients taking urate lowering medication (allopurinol and probenecid)
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istanbul University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Berna Yelken, MD
Role: PRINCIPAL_INVESTIGATOR
Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University
Yasar Caliskan
Role: PRINCIPAL_INVESTIGATOR
Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University
Alaattin Yildiz, Prof, MD
Role: STUDY_DIRECTOR
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University
Numan Gorgulu, MD
Role: PRINCIPAL_INVESTIGATOR
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istanbul Faculty of Medicine
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
200931386
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.